Abstract #4064
Evaluation of MR accuracy in neoadjuvant chemotherapy response assessment in patients showing change of biomarker status
Jeon-Hor Chen 1,2 , Shadfar Bahri 1 , Rita S. Mehta 3 , Philip M. Carpenter 4 , and Min-Ying Su 1
1
Center for Functional Onco-Imaging,
University of California, Irvine, California, United
States,
2
Department
of Radiology, Eda Hospital and I-Shou University,
Kaohsiung, Taiwan,
3
Department
of Medicine, University of California, Orange,
California, United States,
4
Department
of Pathology, University of California, Orange,
California, United States
This study attempted to investigate if the change of
biomarker status after adjuvant chemotherapy (NAC) will
affect MR accuracy in evaluation of residual tumor size.
59 breast cancer patients who received NAC and had
residual tumor size in MRI and pathology and pre- and
post-NAC biomarker information were analyzed. Our study
noted biomarker conversion following NAC did not impact
accuracy of MRI in determining residual tumor size in
Her-2 negative and PR positive breast cancer. In Her-2
positive cancer, when converted into Her-2 negative
cancer, the MR-pathology tumor size difference was
remarkably higher than Her-2 positive cancer without
biomarker conversion.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Click here for more information on becoming a member.
